Ask AI
ProCE Banner Activity

Leveraging BTK Inhibition Strategies in B-Cell Malignancies: Expert Perspectives to Guide Clinical Decisions

Slideset Download
Download this slideset from our live meeting series to learn more about the optimal use of BTK inhibitors as therapy for patients with B-cell malignancies, including MCL, CLL/SLL, WM and MZL.

Released: June 26, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Christopher R. Flowers, MD, MS

Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
MD Anderson Cancer Center
Houston, Texas